Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528722 | Current Opinion in Pharmacology | 2017 | 6 Pages |
Abstract
Gastroesophageal reflux disease (GERD) constitutes a troublesome symptom complex resulting from retrograde passage of gastric contents into the esophagus or extra-esophageal regions. Premature-born, high-risk infants and those with neuro-aero-digestive pathologies are at increased risk. Critical review over the last 3 years was conducted, and current opinions on pharmacological targets include agents aimed at prevention of transient lower esophageal sphincter relaxation, modification of the physico-chemical composition of gastric contents, modification of gut motility, or altering sensory thresholds to ameliorate the troublesome symptoms. As data from well-designed studies is limited in the infant population, information from adult studies has been cited where potential application may be helpful.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Mohamed A El-Mahdy, Fatma A Mansoor, Sudarshan R Jadcherla,